Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.

@article{Bliss2012DiseaserelatedOW,
  title={Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.},
  author={Judith Margaret Bliss and Lucy Suzanne Kilburn and Robert Coleman and John F. Forbes and Alan S. Coates and Stephen E. Jones and Jacek Jassem and Thierry Delozier and J\orn Andersen and Robert J. Paridaens and Cornelis J. H. van de Velde and Per Eystein L\onning and James P. Morden and Justine A Reise and Laura A Cisar and Thomas Menschik and R C Coombes},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 7},
  pages={709-17}
}
PURPOSE Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically important benefits from switching adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane. Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists

  • JF Forbes, J Cuzick
  • Lancet Oncol 9:45-53,
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…